PATHOQUEST

Charles River and Medigen Vaccine Biologics Partner to Advance Next-Generation Multivalent Enterovirus Vaccine

- Charles River Laboratories and Medigen Vaccine Biologics (MVC) are collaborating on characterization and validation of the virus seed bank for MVC's next-generation multivalent enterovirus vaccine. - Charles River will apply Next-Generation Sequencing (NGS) and advanced analytical platforms to support Chemistry, Manufacturing, and Controls (CMC) activities for the vaccine program. - The partnership aims to generate robust data supporting IND applications, IND-enabling non-clinical studies, and future global clinical development. - MVC's proprietary Envacgen Enterovirus 71 Vaccine has already been approved in Taiwan and Vietnam, underscoring the company's established vaccine development capability.